A5090159032- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Folate and B Vitamins Research
- Liver Disease Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Lymphoma Diagnosis and Treatment
- Frailty in Older Adults
- Cholangiocarcinoma and Gallbladder Cancer Studies
The University of Texas Health Science Center at San Antonio
2022-2024
The University of Texas at San Antonio
2023-2024
Murphy Oil Corporation (United States)
2023
South Texas Veterans Health Care System
2023
Audie L. Murphy Memorial VA Hospital
2023
Hematology Oncology Consultants
2022
Durvalumab is approved for the treatment of adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This real-world study describes patient characteristics and durvalumab patterns (number doses therapy duration; initiation delays, interruptions, discontinuations, associated reasons) among VHA-treated patients.This was a retrospective cohort NSCLC receiving at VHA between 1 January 2017 30 June 2020. Patient were presented descriptively.A total 935...
Abstract Purpose This study retrospectively reviewed the outcomes of patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab bevacizumab (A + B) therapy at Veterans Health Administration (VHA). Patients and Methods HCC who received first-line systemic A B VHA between December 1, 2019, March 2022, were selected from electronic medical records (EMR) using ICD-9 ICD-10 codes. Abstractors EMR their index date initiation until death or last visit, period ending on January 31,...
2651 Background: Advanced Hepatocellular carcinoma (HCC) is an aggressive tumor, and most patients have a poor prognosis. Recent clinical trials demonstrated improved survival with molecularly targeted treatment immunotherapy. Atezolizumab plus Bevacizumab (A+B ) the recommended first-line for advanced HCC based on phase 3 IMbrave 150 trial. However, in real-life setting, many do not meet inclusion criteria of this landmark This study proposes retrospective review outcomes receiving A + B...
Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by patients NSCLC a Veterans Health Administration (VHA) population.This was retrospective analysis White Black treated presenting any VHA facility US from January 1, 2017, June 30, 2020. Data...
e24022 Background: Over the last decade, incidence of Hepatocellular carcinoma (HCC) has increased in geriatric population. Atezolizumab plus Bevacizumab (A+B) become an established systemic therapy for patients with HCC. Even aging population and elevated prevalence HCC amongst Veterans, limited studies have explored safety A+B patients. This study aims to investigate toxicity profile as well Palliative Care Hospice utilization within Veteran Health Administration (VHA). Methods: Data were...
4109 Background: The incidence and mortality of HCC are increasing in the USA. disparities have been reported across entirety cancer timeline, from screening to local systemic treatment liver transplant. We aim analyze clinical characteristics, outcomes, racial patients with advanced receiving first-line Atezolizumab plus Bevacizumab (A+B) Veterans Health Administration (VHA) – only health care system USA that provides equal access all patients. Methods: Patients were followed their A+B...
e16195 Background: Atezolizumab plus Bevacizumab (A+B) has been the standard first-line therapy for advanced hepatocellular carcinoma (HCC) patients. There needs to be more data on efficacy and selection of optimal sequences following resistance A+B. Our study aims review treatment patterns disease progression A+B, focusing most common 2nd line utilized by Veterans Health Administration (VHA). Methods: Patients with HCC receiving A+B at VHA between Dec 1, 2019, Mar 2022, were selected...
4107 Background: Most clinical trials use Child-Pugh (CP) for patient selection; this subjective scale was originally developed to assess liver function in cirrhosis, thus cannot be applied HCC patients with non-cirrhotic background. Alternatively, ALBI grade is an objective and validated prognostic system that has demonstrated improved accuracy predict survival decline patients. Our real-world study aims the as a predictive marker of treatment response advanced who received (A+B) within...
e16129 Background: Treatment options for aHCC have drastically improved over the past few years with immunotherapy at forefront. Ongoing studies aim to identify benefit of in combination local therapies, but there are no that analyze impact previous therapy on OS patients who later receive A+B treatment aHCC. This study aims treated first line within Veterans Health Administration (VHA). Methods: Patients receiving systemic VHA between Dec 1, 2019 through Mar 2022 were identified from...
8556 Background: Durvalumab is an FDA-approved immunotherapy for the treatment of adults with UnResectable stage III non-small cell lung cancer (UR-NSCLC) without disease progression following concurrent chemoradiotherapy (CRT). There are limited real-world data regarding initiation delays (TIDs) and reasons them in UR-NSCLC population. Methods: Patients receiving consolidation at Veterans Health Administration (VHA) between January 1, 2017 June 30, 2020 were selected from VHA database using...
e19568 Background: Primary mediastinal B-cell lymphoma (PMBCL) is considered a rare distinct clinicopathological and molecular subtype of diffuse large (DLBCL), mainly affecting females in their 4 th 5 decades [1,2,3]. Since the 1960s, there has been significant increase number immigrants to US; states Florida (FL) Texas (TX) are well known for Hispanic (HI) enriched population. scarce data PMBCL HI; we researched demographics, treatment patterns outcomes H compared Non-Hispanics (NH) from...
8554 Background: The PD-1/PD-L1 pathway is a mechanism of immune evasion and disruption this with checkpoint inhibitors (ICIs) has shown clinical benefit in multiple malignancies. Based on results from the PACIFIC trial, durvalumab approved as consolidation therapy patients (pts) stage III unresectable non-small cell lung cancer (UR-NSCLC) without progression following concurrent chemoradiotherapy (cCRT). Durvalumab been used extensively Veterans Health Administration (VHA) facilities,...